You know the expression – “the more things change, the more they stay the same.” Well if there’s anything that we learned over the last year, it’s that this phrase absolutely does not apply to anything related to IVL.
Welcome to The Catalyst
Change isn't quick. Unless it's when you experience Intravascular Lithotripsy (IVL) for the first time. Stay apprised of our latest news and insights while discovering how a simple and intuitive tool can be The Catalyst to change the way you think about calcium modification.
You know the expression – “the more things change, the more they stay the same.” Well if there’s anything that we learned over the last year, it’s that this phrase absolutely does not apply to anything related to IVL.
Topics: Medical Meetings, Coronary Cases, Coronary Clinical Data, Shockwave C2, Coronary Conferences
From Data to Daily Practice; Disrupting Calcium with IVL across multiple vessel beds.
Topics: Medical Meetings, Peripheral IVL, DISRUPT PAD, Peripheral Conferences, Peripheral Clinical Data
Shockwave is in the midst of preparing to go direct in the UK on 1st of July.
Topics: Insider, Shockwave Breaking News, IVL Technology
One cannot become a calcium expert overnight – it takes time and commitment to go deep on the topic. That’s why we’re excited to embark this month on a year-long education journey that we’re calling the Calcium Masterclass. Over the last year, we’ve been working with Prof. James Spratt (St. George’s University, London) and the team at Optima Education to develop a comprehensive collection of 10 webinars, 5 of which will feature live cases, and a 14-chapter calcium compendium that will be presented by 37 masters of coronary calcium.
Topics: Coronary IVL, Coronary Cases, Shockwave C2, CAD Applications - Eccentric Lesions, CAD Applications - Bifurcations, Coronary IVL - U.S.
IVL use in real world CFA population shows low residual stenosis and 0% complications.
Topics: Peripheral IVL, Peripheral Cases
Recently, SCAI presented a Complex PCI webinar that featured world renowned panelists sharing the latest SCAI guidelines for calcified lesions, which included newly approved coronary IVL.
Topics: Coronary IVL
Welcome to ChalkTalk, our new podcast series where we discuss all things cardiovascular calcium, featuring perspective from our leaders and leading physicians who are using IVL in clinical practice to crack their toughest cases. We plan to bring you the latest cases, insights & evidence surrounding both coronary and peripheral Shockwave IVL.
Topics: Shockwave Behind-the-Scenes, Coronary IVL, Peripheral IVL, IVL Technology, ChalkTalk Podcast
Recently at CRT21, Dr. Matthew Price, Director of the Cardiac Catheterization Laboratory at Scripps Clinic in La Jolla, presented the first sub-analysis of the Disrupt CAD III U.S. pivotal study, looking at clinical outcomes with IVL in lesions <25mm compared to those with ≥25mm. After his presentation, we caught up with Dr. Price to get his perspective on the data and its significance. You can also watch his full presentation at the video below.
Following the recent PMA approval of coronary IVL, Dr. Robert Riley, Medical Director of the Complex Coronary Therapeutics Program, and Dr. John Corl, Medical Director of PAD/CLI Program, of the Christ Hospital in Cincinnati, performed the first commercial U.S. coronary IVL cases. Following their cases, we caught up with Dr. Riley to get his take on using the technology outside of a clinical trial and what advice he has for other physicians before they try the technology.
Topics: Coronary IVL, IVL Case, Coronary Cases, Shockwave C2, Coronary IVL - U.S.
Your first Shockwave IVL newsletter, PulsePoint, has arrived. We’re kicking off with an ambitious recap of 2020, celebrating key milestones and major events for our customers using our peripheral technology across the globe. Released on a quarterly basis moving forward, PulsePoint will be the one stop shop for all the latest news and updates throughout the year. We hope you enjoy our first global edition of PulsePoint.
Topics: Peripheral IVL, Peripheral Cases, PulsePoint Newsletter
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
